Memantine Hydrochloride
Product Images NDC 67046-458

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 67046-458). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Contract Pharmacy Services-pa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Spl-memantine-chemical-structure (Spl Memantine Chemical Structure)

Chemical structure of Memantine Hydrochloride showing the molecular framework with an amino group (NH2) and methyl groups (CH3) attached to a cage-like ring system.*

FDA Label Image

Spl-memantine-figure1 (Spl Memantine Figure1)

A line graph showing mean change from baseline in ADCS-ADL score over 28 weeks of treatment comparing Memantine Hydrochloride and placebo. The X-axis represents weeks of treatment, and the Y-axis shows mean change scores indicating clinical improvement or decline. Memantine Hydrochloride shows less decline over time compared to placebo.*

FDA Label Image

Spl-memantine-figure2 (Spl Memantine Figure2)

A cumulative percentage curve graph depicting patients completing 28 weeks of double-blind treatment. The x-axis shows ADCS-ADL change from baseline, and the y-axis shows cumulative percentage of patients. Two lines compare Placebo and Memantine Hydrochloride groups, illustrating differences in patient response over time.*

FDA Label Image

Spl-memantine-figure3 (Spl Memantine Figure3)

A line graph showing the mean change from baseline in SIB score over 28 weeks of treatment for patients taking Memantine Hydrochloride versus placebo. The x-axis represents weeks of treatment, and the y-axis shows the mean change in SIB score, with lines indicating clinical improvement and decline. Data points for Memantine Hydrochloride and placebo groups are shown with error bars.*

FDA Label Image

Spl-memantine-figure4 (Spl Memantine Figure4)

A cumulative percentage graph comparing patients treated with Memantine Hydrochloride versus placebo. The X-axis shows SIB change from baseline, and the Y-axis shows the cumulative percentage of patients over 28 weeks of double-blind treatment. Data points for Memantine Hydrochloride and placebo are distinguished by open circles and filled squares, respectively.*

FDA Label Image

Spl-memantine-figure5 (Spl Memantine Figure5)

A line graph showing the mean change from baseline in ADCS-ADL scores over 24 weeks of treatment. Two treatment groups are compared: Placebo/Donepezil and Memantine Hydrochloride/Donepezil. The graph indicates clinical improvement or decline with time, with error bars representing the standard error of the mean.*

FDA Label Image

Spl-memantine-figure6 (Spl Memantine Figure6)

A cumulative percentage of patients graph comparing placebo/donepezil and memantine hydrochloride/donepezil over 24 weeks. The X-axis shows ADCS-ADL change from baseline and the Y-axis shows cumulative percentage of patients. Two curves illustrate patient outcomes with each treatment group.*

FDA Label Image

Spl-memantine-figure7 (Spl Memantine Figure7)

A line graph showing the time course of change from baseline in SIB score over 24 weeks of treatment. The graph compares two groups: Placebo/Donepezil and Memantine Hydrochloride/Donepezil, with mean changes plotted against weeks of treatment, illustrating clinical improvement or decline.*

FDA Label Image

Spl-memantine-figure8 (Spl Memantine Figure8)

A cumulative percentage curve comparing patients treated with Memantine Hydrochloride/Donepezil versus Placebo/Donepezil. The x-axis shows SIB change from baseline, and the y-axis shows cumulative percentage of patients over 24 weeks of double-blind treatment, highlighting differences in SIB score changes.*

FDA Label Image

Spl-memantine-label-10mg (Spl Memantine Label 10mg)

Memantine 10 mg tablet label showing a count of 60 tablets. Label includes lot number, pill ID, and expiration date. It states the product is prescription only and packaged by Contract Pharmacy Services-PA. The label advises usual dosage information and storage conditions, confirming each tablet contains 10 mg memantine hydrochloride USP.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.